Patients with celiac disease are at increased risk for infections such as tuberculosis, infl uenza, and pneumococcal pneumonia. However, little is known about the incidence of Clostridium diffi cile infection (CDI) in patients with celiac disease.
INTRODUCTION
Patients with celiac disease (CeD) are at increased risk for infections and their complications, including infl uenza ( 1 ), pneumococcal infections ( 2 ), community-acquired pneumonia ( 3 ), tuberculosis ( 4 ) , and sepsis ( 5, 6 ) . Diff erential rates of infections may refl ect a variety of factors, including hyposplenism, malnutrition/vitamin D defi ciency, altered gut immunity, or mucosal permeability ( 5 ) . Given this heightened susceptibility, it is important to assess the impact of clinically relevant pathogens in patients with CeD.
Clostridium diffi cile infection carries a heavy burden of morbidity and mortality in Western countries, with an estimated 453,000 incident cases and 29,300 associated deaths in the United States in 2011 ( 7, 8 ) . Rates of incident infection, both hospital-and community-acquired, are increasing ( 9 ) . In addition to female, white, and elderly (≥65 years old) patients ( 7 ) , studies also have identifi ed patients with infl ammatory bowel disease (IBD) as a population at higher risk for C. diffi cile infection and its sequelae (10) (11) (12) (13) (14) . While CeD shares characteristics with IBD, including being both immune-mediated and associated with altered microbiota ( 15, 16 ) , the incidence of C. diffi cile infection in patients with CeD compared to the general population has not been evaluated to date. Th erefore, using a well-characterized national Swedish patient cohort, we assessed the risk of C. diffi cile infection in patients with CeD compared to non-CeD controls.
METHODS

Study population
We performed a population-based cohort study of patients in Sweden with duodenal villous atrophy consistent with CeD. Th e study population was derived as described previously ( 17, 18 ) . Patients with CeD were identifi ed via Systematized Nomenclature of Medicine (SnoMed) codes corresponding to villous atrophy among all small intestinal biopsy specimens submitted to Swedish pathology departments from July 1969 to February 2008. Time of entry into the study was defi ned as date of biopsy for patients with CeD or the corresponding date for matched controls. Patients who had already been diagnosed with C. diffi cile infection prior to that index date (date of diagnosis of CeD or corresponding date for controls) were excluded from the analysis. Th e follow-up period continued for each patient until development of C. diffi cile infection, death (identifi ed via the Swedish Total Population Register), emigration, or 31 December 2009. Via the government agency Statistics Sweden, each patient with CeD was matched with up to fi ve controls (mean 4.82) without CeD based on age (in years), gender, and county.
Primary outcome
Th e primary outcome was incident C. diffi cile infection, as identifi ed by outpatient or inpatient visits with corresponding International Classifi cation of Disease Codes indicating C. diffi cile infection (ICD-10 A047). Th is diagnosis code was introduced in Sweden on 1 January 1997, and was fi rst diagnosis code to be specifi c to C. diffi cile ; individuals whose follow-up time ended before that date were therefore excluded from the analysis.
Statistical analysis
We performed stratifi ed Cox proportional hazards models to compare patients with CeD to matched controls with regard to their risk of incident C. diffi cile infection. As socioeconomic status may be associated with CeD diagnosis, results were adjusted for the subject's educational attainment level (or for subjects <18 years, their parents) ( 19, 20 ) . We then performed stratifi ed analyses based on age of CeD diagnosis, gender, and calendar period of study entry.
To assess robustness of our fi ndings, we performed several sensitivity analyses. First, so as to increase the chance that the use of a C. diffi cile diagnosis code represented a true infection, we restricted the defi nition of the outcome of C. diffi cile infection to subjects with at least two visits with a diagnosis code of C. diffi cile . Second, we repeated the overall risk assessment, now without adjusting for education level.
Time-stratifi ed analysis (1997-2009) .
In addition to the overall hazard ratio (HR), we subsequently recalculated the overall risk assessment, now restricting the population to those CeD patients and their corresponding controls whose date of biopsy/study entry occurred on or aft er 1 January 1997, since ascertainment of the date of C. diffi cile diagnosis was available from that date onward. We then calculated HRs stratifi ed according to time elapsed since CeD diagnosis (<1 year, 1-5 years, or >5 years) based on the fi nding that risk of morbidity diminishes over time following CeD diagnosis ( 3, (21) (22) (23) .
Health-care utilization (2001-2009) .
Patients with CeD may be more likely to be diagnosed with C. diffi cile infection because of increased opportunities for testing, given that CeD is a chronic condition that entails contact with the health-care system. Th is increased contact with health care may in turn increase the risk for the development of C. diffi cile infection, given the exposure to antibiotics or the presence of C. diffi cile in the health-care setting. We therefore calculated the mean number of annual outpatient visits (excluding visits associated with a diagnosis of C. diffi cile infection) in CeD patients and matched controls; we limited this analysis to 1 January 2001 onward, since visit volume data were only available since that date. We then measured the association between CeD and C. diffi cile infection aft er adjusting for the number of outpatient visits.
Medication use (2005-2009) .
We performed two additional analyses that incorporated medication use as confounding or mediating the association between CeD and C. diffi cile infection. First, we adjusted for exposure to at least one prescription for a proton pump inhibitor (PPI) from 1 July 2005 (the date of inception of the Swedish Prescription Drug Register) and 31 December 2009 (the study end). Th is register records prescriptions from both inpatient and outpatient care (including prescriptions from general practitioners) ( 24 ) but not drugs administered in the hospital or sold over the counter. We then assessed recent antibiotic use (defi ned as occurring in the 180 days preceding the C. diffi cile infection) in patients with CeD and controls to examine associations with particular agents. Among subjects with C. diffi cile infection during that time period, we compared CeD patients to controls using the χ 2 -test with regard to recent exposure to one of four antibiotic classes or groupings: penicillins, fl uoroquinolones, macrolides, and other antibiotics.
We performed statistical calculations using SAS version 9.4 (Cary, NC, USA). All HRs are reported with corresponding 95% confi dence intervals, and all reported P values are two-sided. Th is study was approved by the Regional Ethical Review Board in Stockholm, Sweden which required no informed consent since this was a strictly register-based study ( 25 ) .
RESULTS
Patient characteristics
Of 28,375 patients with CeD and 141,631 matched controls, 36 patients with CeD and 43 controls were excluded due to prior C. diffi cile infection. Th e resulting study populations included 28,339 patients with CeD and 141,588 controls, matched for age, sex, and calendar year of entry ( Table 1 ) .
Th e mean follow-up time for all patients was 11. with CeD compared to controls was 2.01 (95% confi dence interval (CI) 1.64-2.47, P <0.0001). When the HR was calculated without adjustment for education level, fi ndings were essentially the same (HR 2.00, 95% CI 1.64-2.45; P <0.0001). When we redefi ned C. diffi cile infection as requiring two or more separate visits with a relevant diagnosis code, the association remained between CeD and C. diffi cile (HR 2.16, 95% CI 1.50-3.10; P <0.0001). Th e association between CeD and C. diffi cile infection was present when considering separately those cases of C. diffi cile infection ( n =445) fi rst diagnosed in the inpatient setting (HR 1.93; 95% CI 1.56-2.40, P <0.0001) and those cases ( n =48) fi rst diagnosed in the outpatient setting (HR 2.72; 95% CI 1.52-4.87, P =0.0008). On stratifi ed analysis ( Table 2 ) , signifi cantly increased risk of C. diffi cile infection was present in both genders, across age groups, and across calendar periods. Formal tests for interaction showed no signifi cant diff erences between categories of gender, age group, or calendar period with regard to the association between CD and the development of C. diffi cile infection.
Time-stratifi ed analysis . When we examined the subset of this cohort diagnosed with CeD on or aft er 1 January 1997, the association between CeD and C. diffi cile remained similar (HR 2.05, 95% CI 1.54-2.72; P <0.0001). Th e risk of infection was highest in the fi rst 12 months aft er CeD diagnosis (HR 5.20, 95% CI 2.81-9.62; P <0.0001), but remained elevated in the 1-5 years aft er diagnosis compared to controls (HR 1.85, 95% CI 1.22-2.81; P =0.004, 
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Celiac Disease and C. difficile Table 3 and Supplementary Figure 1 online) . Beyond 5 years aft er CeD diagnosis, the association between CeD and C. diffi cile infection was no longer statistically signifi cant (HR 1.42; 95% CI 0.85-2.38). Th is change in HR over time was signifi cant ( P value for heterogeneity=0.003).
Health-care utilization . We examined the subset of this cohort diagnosed with CeD on or aft er 1 January 2001, now adjusting for the mean number of outpatient visits. Patients with CeD had a mean 2.8 outpatient health-care visits per year (excluding visits with a diagnosis code indicating C. diffi cile infection), compared to controls, who had a mean 1.7 outpatient visits per year ( P <0.0001). Aft er adjusting for outpatient healthcare visits, the association between CeD and C. diffi cile infection was no longer statistically signifi cant (HR 1.08, 95% CI 0.64-1.80), while each additional annual outpatient visit was associated with an increased risk of C. diffi cile infection (HR 1.23, 95% CI 1.16-1.30).
Medication use . At least one prescription for a PPI (omeprazole, esomeprazole, pantoprazole, lansoprazole, or rabeprazole) was noted in 5,998 (21%) of 28,339 CeD patients and 19,215 (14%) of 141,588 controls ( P <0.0001). Aft er adjusting for PPI exposure, the association between CeD and the development of C. diffi cile infection remained signifi cant (HR 1.68, 95% CI 1.32-2.14, P <0.0001).
Antibiotic data were available for 251 (50.9%) of the 493 patients with C. diffi cile infection, based on temporal overlap with the Swedish Prescription Drug Registry. Of these 251 subjects, 165 (66%) had been prescribed an antecedent antibiotic. (None of these 165 subjects was prescribed >1 class of antibiotic.) Although patients with CeD were less likely than controls to have taken penicillins and more likely to have taken quinolones, these diff erences were not statistically signifi cant ( P =0.32, Table 4 ). Th ere were no significant diff erences in the distribution of antibiotic exposure between CeD patients and controls across all treatment categories: penicillins, quinolones, macrolides, other antibiotics, or no antibiotics.
DISCUSSION
C. diffi cile infection is associated with a high burden of morbidity and mortality in Western countries, but its incidence among patients with CeD has not been assessed previously. In this population-based cohort study, patients with CeD had double the risk of C. diffi cile infection compared to that of controls with fi ndings that remained signifi cant regardless of adjustment for education level and PPI use, as well as stratifi cation by age, sex, and study period of enrollment. Among the strengths is the large statistical power (and tight 95% CI=1.64-2.47) but also our access to data on potential confounders and a comparison of antibiotic exposures among individuals who developed C. diffi cile infection.
Th ese results extend the prior literature that patients with CeD are at increased risk for infections, including infl uenza, community-acquired pneumonia, and tuberculosis (1) (2) (3) (4) (5) . Possible etiologies for these trends, including hyposplenism, malnutrition, vitamin D defi ciency, and increased mucosal permeability, have been posited. It is possible that the increased risk of developing C. diffi cile infection is related to the higher rate of these other infections, in that antibiotic use to treat the latter may increase the risk of the former. Another biologically plausible explanation may be that CeD patients are at increased risk for C. diffi cile infection due to the altered colonic microbiota that accompanies C. diffi cile infection ( 8, 26 ) . Although disrupted microbiota may be attributable to antibiotic exposure, in our study, antibiotic use occurred at similar rates in those who developed C. diffi cile infection, regardless of whether they had CeD or were controls. Th is fi nding contrasts with data in patients with IBD, who are less likely to have been exposed to antibiotics than controls with C. diffi cile infection ( 11, 27 ) . Gut microbiota composition diff ers in patients with CeD compared with healthy controls, with an increase of certain Clostridia species ( 16, 28, 29 ) . One possible explanation for the increased risk of C. diffi cile infection among patients with CeD relates to the patient visits showed an even stronger association between CeD and C. diffi cile infection (HR 2.16, 95% CI 1.50-3.10). As we were only able to ascertain the diagnosis of C. diffi cile infection starting in 1997, it is possible that patients with CeD with a history of C. diffi cile infection preceding their CeD diagnosis were included in this cohort if the infection occurred prior to 1997; however, given that the observed prevalence of C. diffi cile infection was <0.5% of the cohort, such misclassifi cation is likely to be rare. Given the limited overlap between the Swedish Prescription Drug Register (established on 1 July 2005) and our cohort (in which the last new entrants were recorded in 2008), our analysis of antecedent antibiotic use was focused on a subset of subjects infected with C. diffi cile , and our adjustment for PPI use could not take into account prescriptions for those agents that preceded 2005. Patients with CeD are more likely to be prescribed antibiotics before their CeD diagnosis ( 15 ) , and thus diff erential antibiotic utilization aft er diagnosis may account for some of the increased C. diffi cile risk. We have previously reported that patients with CeD were more likely to have been prescribed PPIs prior to their CeD diagnosis than were controls ( 34 ) , and in the present analysis, PPI use was more common aft er diagnosis with CeD among those patients followed during the period covered by the Prescription Drug Register. Nevertheless, aft er adjusting for PPI, the association between CeD and subsequent C. diffi cile remained signifi cant (HR 1.68, 95% CI 1.32-2.14). Indeed, it is unlikely that diff erential PPI use is driving a large diff erence in C. diffi cile risk, given the relatively modest risk magnitude of the association between that class of medications and C. diffi cile infection ( 35 ) .
Diff erential rates of health-care consumption (as evidenced by a larger mean number of outpatient visits per year among CeD patients compared to controls) may be contributing to the observed diff erence in C. diffi cile diagnosis rates. Since patients with CeD may be more likely to seek evaluation for diarrhea than healthy controls, they may be more likely to be diagnosed with C. diffi cile infection. Indeed, we found that the association between CeD and C. diffi cile infection was no longer signifi cant aft er adjusting for the number of health-care visits. Th is raises the possibility that healthcare contact may be mediating the relationship between CeD and C. diffi cile. Even without personal receipt of antibiotics, exposure to healthcare, both in outpatient and inpatient settings, may be a risk factor for the development of C. diffi cile infection ( 36, 37 ) . However, this also raises the possibility that the association between CeD and C. diffi cile is, at least in part, driven by increased clinical evaluation in patients with CeD compared to the general population. Nevertheless, the association between CeD and C. diffi cle infection was signifi cant when considering separately outpatient and inpatient visits, the latter of which may be less likely to refl ect self-reporting of symptoms. Th is fi nding suggests that health-care visits are serving as a mediator on the causal pathway between CeD and the development of C. diffi cile infection.
In conclusion, in this population-based cohort study, we found that the incidence of C. diffi cile infection was signifi cantly increased in patients with CeD than in controls, and that risk of C. diffi cile infection was highest in the fi rst year aft er CeD diagnosis. Among patients who developed C. diffi cile infection, treatment with a gluten-free diet. Although this diet carries clinical and histologic benefi t to patients with CeD, gluten restriction may have downstream consequences with regard to pathogen defense. In a study of healthy volunteers without CeD, the gluten-free diet was associated with a reduction of Bifi dobacterium and Lactobacillus populations, bacteria that may be protective against enteric infections, including those due to C. diffi cile ( 30 ) . In one study of 120 patients with CeD, of 10 who had refractory diarrhea thought to be due to uncontrolled CeD, 6 were found to have C. diffi cile ; the CeD patients may have been at increased risk due to decreased diversity involving Bacteroides , Prevotella , and Bifi dobacteria ( 31 ) . One previous study found that children with IBD had carriage rates of C. diffi cile nearly 10 times greater than those of children with CeD, though in that study those with IBD included inpatients (which likely included patients in the midst of a disease fl are) while those with CeD were restricted to outpatients ( 11 ) .
We found that the risk of incident C. diffi cile infection was highest at the time closest to CeD diagnosis: the HR for C. diffi cile infection was 5.20 in the fi rst year following diagnosis, and decreased to 1.85 in the 1-5 years following diagnosis. Although the point estimate remained elevated beyond 5 years aft er diagnosis, the diff erence was not signifi cant. Th ese fi ndings are consistent with prior studies showing that patients with CeD have highest rates of co-morbid diseases in the initial time period following diagnosis. Th is might refl ect protopathic bias, for example, patients with pre-existing C. diffi cile whose evaluation for diarrhea reveals previously asymptomatic CeD. However, this also might refl ect that patients have the greatest degree of intestinal infl ammation at the time of initial CeD diagnosis and prior to treatment ( 22, 23, 32 ) . Nevertheless, we found that the overall risk estimate was similar regardless of whether we included the cohort diagnosed from 1969 to 2008 (HR 2.01, 95% CI 1.64-2.07), or when we restricted the analysis to those subjects whose date of inclusion occurred in the year 1997 and onward, when we were fi rst able to ascertain the presence of C. diffi cile infection (HR 2.05, 95% CI 1.54-2.72). Th e fact that those diagnosed prior to 1997 had an increased risk of the outcome of C. diffi cile infection raises the possibility that there is a long-term risk of C. diffi cile that diminishes but does not resolve in the long term. Patients presenting for evaluation of persistent diarrhea are likely to be tested for both infectious and non-infectious etiologies, which may boost identifi cation of C. diffi cile around the time of CeD diagnosis. Regardless of cause for the stronger association during the peri-diagnosis period, the persistently increased risk of C. diffi cile infection beyond the fi rst year of CeD diagnosis suggests a biological basis for the association.
Our study has several limitations. Th e C. diffi cile diagnoses refl ected patient visit diagnosis codes, which may have been falsely coded and we did not have access to stool samples. Although the specifi city for the use of a single diagnosis code for C. diffi cile has been found to be high ( 33 ) , there is the possibility that in clinical practice it might be used as a "rule out" code. For example, in a patient being evaluated for C. diffi cile infection, although test results
were not yet available, the diagnosis code for C. diffi cile might nevertheless be used. To minimize this eff ect, sensitivity analysis requiring that C. diffi cile diagnosis be present during at least two
